SCHEMBL1318952

SCHEMBL1318952

CCCCC(C(=O)O)N(c1c(NC(C)=O)ccc2ccccc12)S(=O)(=O)c1cc(Cl)cc(Cl)c1.c1cc2cc-2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
ACLY P53396 3/20 0.36
HSD17B10 Q99714 1/20 0.35
SERPINE1 P05121 1/20 0.34
ADORA1 P30542 1/20 0.33
PTPN1 P18031 1/20 0.33
KDM4E B2RXH2 3/20 0.33
PSEN1 P49768 2/20 0.33
PSEN2 P49810 2/20 0.33
APH1B Q8WW43 2/20 0.33
NCSTN Q92542 2/20 0.33
APH1A Q96BI3 2/20 0.33
PSENEN Q9NZ42 2/20 0.33
TACR3 P29371 1/20 0.33
KMT2A Q03164 2/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110219 0.85 ACLY (0.37) ALDH1A1ACLYPTPN1KDM4EPSEN1
SCHEMBL1110639 0.81 KEAP1 (0.45) ALDH1A1ACLYKMT2A
SCHEMBL1320030 0.81 ACLY (0.36) ACLYADORA1PTPN1PSEN1PSEN2
SCHEMBL1110375 0.80 MMP13 (0.39) ACLYPSEN1PSEN2APH1BNCSTN
SCHEMBL1110199 0.80 ACLY (0.37) ACLYPTPN1PSEN1PSEN2APH1B
SCHEMBL1318290 0.80 PSEN1 (0.35) ACLYPSEN1PSEN2APH1BNCSTN
SCHEMBL1110364 0.76 ITGA4 (0.35) ACLYPSEN1PSEN2APH1BNCSTN
SCHEMBL1110573 0.74 PSEN1 (0.38) ACLYPTPN1KDM4EPSEN1PSEN2
SCHEMBL1110297 0.73 CA12 (0.41) ALDH1A1ACLYKDM4EPSEN1PSEN2
SCHEMBL1110475 0.73 MAPT (0.38) ALDH1A1ACLYPTPN1KDM4EPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 ALDH1A1 49/4885ACLY 1173/4885HSD17B10 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.